Dr. Gasink is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Spruce St
3 Dulles Building
Philadelphia, PA 19104Phone+1 215-349-8222- Is this information wrong?
Education & Training
- University of Pennsylvania Health SystemFellowship, Gastroenterology, 2001 - 2004
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
- University of Virginia School of MedicineClass of 1998
Certifications & Licensure
- PA State Medical License 2002 - 2018
Publications & Presentations
PubMed
- 74 citationsFive-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Subrata Ghosh, W...> ;Clinical Gastroenterology and Hepatology. 2021 Feb 19
- 114 citationsIM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.Stephen B. Hanauer, William J. Sandborn, Brian G. Feagan, Christopher Gasink, Douglas Jacobstein, Bin Zou, Jewel Johanns, Omoniyi J. Adedokun, Bruce E. Sands, Paul Rut...> ;Journal of Crohn's & Colitis. 2020 Jan 1
- 104 citationsCombination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc AnalysisJean-Frederic Colombel, Omoniyi J. Adedokun, Christopher Gasink, Long Long Gao, Freddy Cornillie, Geert R. D'Haens, Paul Rutgeerts, Walter Reinisch, William J. Sandbor...> ;Clinical Gastroenterology and Hepatology. 2019 Jul 1
- Join now to see all
Press Mentions
- New Analyses Suggest Favorable Results for STELARA (Ustekinumab) When Used as a First-Line TherapyNovember 1st, 2021
- New Analyses Suggest Favorable Results for STELARAOctober 25th, 2021
- Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI TrialFebruary 19th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: